Skip to content
May 08 2015
Equity Strategies

Small Cap Biotech Valuations: Proceed With Caution

  • May 8, 2015

While Large/Mid Cap Biotechnology companies are boasting rising profitability, better cash flows, and stronger drug pipelines, the Small/Micro Cap Biotech firms, in general, have little tangible to show and valuations may be above the comfort zone.

tags

Biotechnology GS Scores Group Report Small/Micro Biotech

Login

For full access, please enter your credentials.

About The Author

Jun Zhu / Sr. Research Analyst & Co-Portfolio Manager

Jun Zhu Sr. Research Analyst & Co-Portfolio Manager

Jun is a Senior Analyst at The Leuthold Group, LLC, and a Co-Portfolio Manager of the Leuthold Core Investment Fund.

current issue

November 2020
Volume 40
No 11

featured articles

recent tags
[ALL]

COVID (1) Growth (114) Value (110) Factor Performance (8) Momentum (168) Standard-Deviation (1) FAANG (1) Large Cap Growth (3) Commodities (103) Energy (81) Commodity Stocks (11) GS Scores (304) CPI/PPI Ratio (4) Inflation (529) Emerging Market Stocks (2) Valuations (287) Emerging Markets (84) Emerging Vs. Developed Markets Allocation Strategy (2) Asset Allocation Strategy (7) All Asset No Authority (9)